Competitor Analysis: Cardiovascular Peptides
Delivery costs do not apply or are included.
Ask a question about this product
Competitor Analysis: Cardiovascular Peptides
The present Competitive Intelligence Report about Cardiovascular Peptides used to treat or prevcent heart failure, myocardial infarction, thrombosis, hypertension, peripheral vascular diseases, hemostasis and wound sealing provides a competitor evaluation in the field of R&D projects with cardiovascular peptides as of October 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of current active projects in research and development of cardiovasuclar peptides. In addition, the report lists company-specific R&D pipelines of cardiovascular peptides. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Competitor Analysis: Cardiovascular Peptides
Table of Contents
- 2013 Sales of Major Cardiovascular Peptides
- Acute Care & Reperfusion Injuries
- Heart Failure
- Coronary Ischemia & Myocardial Infarction
- Cardiometabolic Disease & Atherosclerosis
- Peripheral Vascular Disease
- Hypertension
- Pulmonary Artery Hypertension
- Hemostasis, Wound Sealing & Prevention of Thrombosis
- Hematologic Diseases
- Corporate Cardiovascular Peptide R&D Pipelines